{"name":"Retina Vitreous Associates of Florida","slug":"retina-vitreous-associates-of-florida","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPTEZfU09RbE1hbjU0aldJSkFEMXk1a0REZVRoUWtoelJhdW91X0dIcTZKSHJCRHJ1OHF4M01NUmFQdElpNm5JaHQ1OE1hcnI4WGJwb2F4LW9PNnJsRnBUNlVBWHcyOFJtR1hnZXd4Z19MWEQwRDBNaktCMmY4azYwNGpDeWQ3LVBYUDZxNTIxbjVLaXc?oc=5","date":"2026-04-07","type":"pipeline","source":"Ophthalmology Times","summary":"Eichenbaum Acorns Preview: Future of retina care - Ophthalmology Times","headline":"Eichenbaum Acorns Preview: Future of retina care","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMDA3UjJ6SWhfRlViYURpTEVYWmlrTHphX3J0ZGJxX3NzcWtVTWxfWmxYd25ZWHFDSXBkUXcxekZnYzB3YS12dDNBNHBoQWxBeUJNcnJ3MWZhUW5pNEVQbEZKand1WTEyWnNXeXZmYXRRSEdKMmw0OGxfZHltTkVEcmZxSmljdjRIdXd5ckVrdEZWdTlkNUtBeU5OcXV4VEV6WEVuLWpEcjRiUms4X0o5MGlFLW82Z3J5Y1AxWVFCdnBnNm_SAcoBQVVfeXFMTnNCS0VhNG4xU20zaTdnZmFtbDAtN3JrTEJfNFdpSV9ycG5qQzZHMHhLclNxWDc0ZFgzTmlUQjY0dm9OTzNleURMbXMtUHpjelUxMnhxcWpncG05a1haY3dWd3RzLVVqTUVYWWllN2ZXejFGQmhpQ2pyLUJtd2tNejczSDBRSk02eGhqeGxtMFdpUEV3eUF5UDVIWTYyeXRfZjdTeFlrNDBjTi13WkM1UFp3LVEzWHBCSDE1enJtdVpScU5IcVZlUTl4Zw?oc=5","date":"2026-04-05","type":"trial","source":"Indian Pharma Post","summary":"Innovent Biologics’ OLN324 shows breakthrough results in vision disease study - Indian Pharma Post","headline":"Innovent Biologics’ OLN324 shows breakthrough results in vision disease study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPSUp1OEk2VlpZeUY0aXVQNUxZVmJTWFA4eVVYOU5vRm50NzhvVl9EdTFXWDlpNi1BU19fM0Q2eHAwZ1NacE9LcFhORTlYR3Bwc0NqVVB0Q2dPOTBpcEt4YnVzYkswamJkenZlVS0zOE9CMHNUUUNzQVFUNnhHVnN2ci1NMDA2ZTJzMFd3M2VDbE5yUkZuenc?oc=5","date":"2026-03-29","type":"pipeline","source":"Ophthalmology Times","summary":"Eichenbaum Acorns Preview: Importance of residency - Ophthalmology Times","headline":"Eichenbaum Acorns Preview: Importance of residency","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5NYzQyZmxhZXA1RnBUMmFyUGV5WnVpUzBOUzZvaVl6NmdpYTRkWnpfWEdlNWd2YVNDVFh4bkpUNE1icFlnUFl4VkpDbFhXRlRsVHBsaG9kZE9Uc1p5LTA0?oc=5","date":"2026-01-09","type":"trial","source":"Nature","summary":"Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea Study - Nature","headline":"Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQTV81U1FqZ2h2N0ljMXU1cEZFd0FRcUFJVWl6aExRVFFXd01RNV8yUHRfR3J2SGk0MFhQNUNQWGhXMnVTZHVWaDR1SDlHYXVtbDZ5SmdQQ2tiR1JncXJDOTdDZ0tYRWxMQnZuVGNHWERzbDlreDBRNkI0R0V2X3F0LUpiVlkxXzROU3BpWEtCLVVTQm13aTMwY0ZqX2hmTF9WS3BHNzVwTl9VQmhtcGZkWVB5UQ?oc=5","date":"2025-10-20","type":"regulatory","source":"Ophthalmology Advisor","summary":"Foselutoclax Delivers Durable Vision Benefits in Diabetic Macular Edema - Ophthalmology Advisor","headline":"Foselutoclax Delivers Durable Vision Benefits in Diabetic Macular Edema","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPeThPOGptTk50ZS1CN1ZZUTVtSGpfM0NBNVhzUVBBUmIteWFqcDU1V0tGN1dsTk9PTmpjSnRnN1huZmZ2TVBQZGFodmdWNVpubEpmQjI3QS1YMzQ0N0Y2SW4zTUhEUFBydEpNQ3dMTEE0NzNOWExTazVrQ3RCckJRQkpUdjlTTzlscFRENDBEVXlfTWhDZEx5cU00QUJjcFhKYmRrMVdMeUtwS0l5bjNOOGZ0TW92TG1sY01PSUlCNA?oc=5","date":"2025-10-02","type":"pipeline","source":"Modern Retina","summary":"Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME - Modern Retina","headline":"Eichenbaum Acorns: A leadership conversation with Rishi P. Singh, MD, FASRS, on advancing CME","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE91VWliWWRRMEhWdzI5cTlYaC1BS1EyY0JFYXpNR1ZYQnhCME1WOEZLSWRFZmk3ZFFVckpNc2ZvT29pbGU5N2JqbG5XZUlOT3ZkdHkwN3RwdnpZTFFmeU5JTkYyR1M?oc=5","date":"2025-10-01","type":"pipeline","source":"MedPage Today","summary":"What's on the Horizon for Age-Related Macular Degeneration? - MedPage Today","headline":"What's on the Horizon for Age-Related Macular Degeneration?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPYTN0Q1JEWXJkaVJpYmdvRklIU1lhODNFekJWd0R6WDRmcUNQcmIzWDBjNXZZblozaXFBU0puY0VUY2dnU2dBdjVaZ0JkRl92a1ZsUUgxZG9QVWZwWlMwUHp1V2EwWlA2LVdYZkhLbXBYZXE4aFAzRmVvZU9OTlFKODlhR3k4WGY4SGNPWGZxRW9INkJIQjlXS1FJb2ZKVDEtV1ZXc1hhY0p4REpWVllLcGtGaXBPSTlNa2VEM25CTXZ2aU9mNTQtdURfUGF5X2JhZ1hFejA0UC1jM0twSnZXVlhqREctSnFBYy1MNDRPOXY5ODlpSVhmbnU2TQ?oc=5","date":"2025-06-17","type":"pipeline","source":"BioSpace","summary":"Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI Platform - BioSpace","headline":"Amaros Closes Series A Financing, Expands Advisory Board to Accelerate Market Entry of the EvidenceEngine™ Ophthalmic AI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOVThndkpGUm80andDRkZTSmU5VWMzQmNycE03bmtIOUxyMW5MQUhsLUY2d3lzbFdBOXpfZGt5M25VX0ptMEZHNTlWOGF1ZVBkX2FmWC0wTkNrRjB2YUxkVHJGbVNfbkRnQlBuSUlUdzl1cmo4VzlGMjlaOUNIX3pyem1CeGRMX2tkMVVnV1VGMV9WVUc3S21CTV85YnFWanpVYUw3SHA5SUR0eVBZQ1cxQWEzckFjRnU1b3lrRklLT044TnNTaGdTVjhfWEk2dnplVkgwNjZ0ank?oc=5","date":"2024-10-06","type":"pipeline","source":"Ophthalmology Advisor","summary":"Neovascular AMD: Treatment Durability, Risk of Undertreatment, and Drying the Macula - Ophthalmology Advisor","headline":"Neovascular AMD: Treatment Durability, Risk of Undertreatment, and Drying the Macula","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOZnhYMmE4M0QxUndmdUM5bGhmNkg1ckNpb1dLWG9UaEhSS19LME55Y0lxRDN4Z05qYTBrV3hzUjVCTjJqNmhRN1N5MlhGWWVZWjNwaVMwMExaX2J1RjJhRUs1ak5RU0thcjMzWVJQdUY1dU1lNmV6ZkZkTWh5bGI2OU9qUEo2a21QZlR0Z0Z1NVhwUnpQejd0ZzByWmZfR0wyMXA0U29acUtEblJOR3lKY2dudXpSV2tvaUs4RUJn?oc=5","date":"2024-09-12","type":"patent","source":"Ophthalmology Times","summary":"Biosimilars for retinal diseases: The long and winding road into clinical practice - Ophthalmology Times","headline":"Biosimilars for retinal diseases: The long and winding road into clinical practice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPako0amc5ZGpBZE9Gekg2UG85U2RDY1BPZmlydEJhdkZHeFkza3ZaTjg5cGlWbnVhcGhXZTBnZWZiNkJhaUd3eVRTalE0SGxBU1QxTzl6OWF0b3E5LVYzZmJwN0pDRG1SbXdRT05rWXZyaEFqZGpTNHhFZzd2dl9XajdvdG1wTklCZDlVYi16anZTMGoyemJpWGF3Wk1mOHItcEZmbGstU2k1dXdMTkgwenFQSUFBZ0xDS1l4ekZzR24wQUJjcVNPUzRVTjhsUk45UndPb0hRRU5mOTdGN3NuMVNMdnQ0QWVoWmVVOA?oc=5","date":"2024-07-19","type":"pipeline","source":"Managed Healthcare Executive","summary":"The Syfovre Balancing Act. The Retinal Vasculitis Risk Is Real But Research Also Points to Benefits | ASRS 2024 - Managed Healthcare Executive","headline":"The Syfovre Balancing Act. The Retinal Vasculitis Risk Is Real But Research Also Points to Benefits | ASRS 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB0RXRadEdJcjBERi1SLXd4bnVEWkpHc2ZpYllaT3pUSTBvVmVzeENleHVaczV6Vkd3cnVqdlV4eDhkRVVOQUw2ZE5HREtqWEVvd3FJTzRiZzNlQnZJclFZ?oc=5","date":"2024-04-15","type":"pipeline","source":"Nature","summary":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy - Nature","headline":"Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}